Johanna Röstin
Conseiller Juridique Général chez VIVESTO AB
Profil
Johanna Röstin currently works at Vivesto AB, as Chief Regulatory Officer.
Ms. Röstin also formerly worked at OxThera AB, as Director-CMC, Program Management & Regulatory and Swedish Orphan Biovitrum AB, as Manager-Global Senior Regulatory Affairs.
Ms. Röstin received her graduate degree from Royal Institute of Technology.
Postes actifs de Johanna Röstin
| Sociétés | Poste | Début |
|---|---|---|
| VIVESTO AB | Conseiller Juridique Général | 01/10/2021 |
Anciens postes connus de Johanna Röstin
| Sociétés | Poste | Fin |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Conseiller Juridique Général | - |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Conseiller Juridique Général | - |
Formation de Johanna Röstin
| Royal Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |